Genomics Screening for Antiangiogenesis Drugs

描述（由申请人提供）：我们将开发一个系统，用于测试新的 使用源自以下的血管内皮细胞（VEC）的抗血管生成化合物 新鲜的人体肿瘤在第一阶段，我们将验证拟议的协议， 将DNA微阵列数据与关于SU 5416的当前信息相关联， SU6668抗血管生成活性，从而为II期奠定基础 用不同浓度的抗肿瘤药物处理肿瘤血管内皮细胞， 抗血管生成药物。SU5416和SU6668阻断信号转导 关键的促血管生成生长因子受体的活性和选择性 靶向肿瘤血管的形成。主要假设是 在I期试验中测试的是，用SU 5416或SU 6668治疗肿瘤VEC将 导致药物特异性的基因表达变化， 血管生成途径。 Oncotech在抗血管生成药物发现领域的主要战略优势是新鲜肿瘤标本的可用性和持续流动。 拟定商业应用： 拟议的测试将在Oncotech为生物技术公司进行，按服务收费。预计2005年Oncotech将获得超过15，000份新鲜肿瘤标本，因此，拟议商业模式的潜在收入可能达到每年1800万美元。到2005年，抗肿瘤血管生成药物的全球市场规模将达到30亿美元。

DESCRIPTION (provided by applicant): We will develop a system for testing new anti-angiogenesis compounds using vascular endothelial cells (VEC) derived from fresh human tumors. In Phase I we will validate the proposed protocol by correlating the DNA microarray data with current information on SU5416 and SU6668 anti-angiogenesis activity, thereby laying a foundation for Phase II studies on microarray analysis of tumor-derived VEC treated with various anti-angiogenesis drugs. SU5416 and SU6668 block the signal transduction activity of critical proangiogenic growth factor receptors and selectively target the formation of tumor vasculature. The principal hypothesis to be tested in Phase I is that treatment of tumor VEC with SU5416 or SU6668 will result in drug-specific changes in the expression of genes involved in angiogenesis pathways. The main strategic advantage of Oncotech in the field of anti-angiogenesis drug discovery is the availability and continuous flow of fresh tumor pecimens. PROPOSED COMMERCIAL APPLICATION: The proposed testing will be performed at Oncotech for biotechnology companies on a fee-for-service basis. With over 15,000 fresh tumor specimens projected for Oncotech in 2005, the potential revenues from the proposed business model may reach $ 18 mln per year. The total global market size for anti-angiogenesis drugs in cancer could reach $ 3 billion by 2005.